acalabrutinib (Calquence)

following an abbreviated submission:

acalabrutinib (Calquence®) is accepted for restricted use within NHSScotland.

Indication under review: in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

SMC restriction: acalabrutinib in combination with venetoclax only.

Acalabrutinib in combination with venetoclax offers an additional treatment choice in the therapeutic class of Bruton tyrosine kinase (BTK) inhibitors to be used in combination with B-cell lymphoma-2 inhibitors.

Another Bruton tyrosine kinase (BTK) inhibitor was accepted for use under the orphanequivalent medicine process.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.